December S&P 500 futures (ESZ23) are down -0.76%, and December Nasdaq 100 E-Mini futures (NQZ23) are down -0.92% this morning as the benchmark U.S. 10-year yield hit 5% for the first time since 2007 while...
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -35.90% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.
Collaboration will extend the applications of each company's platform through discovery and development of novel lipid nanoparticles using Generation Bio's proprietary stealth cell-targeted lipid nanoparticle...
The average of price targets set by Wall Street analysts indicates a potential upside of 183.8% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable,...
The consensus price target hints at a 176% upside potential for Generation Bio Co. (GBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings...
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -4.76% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cash balance of $312.2M expected to fund operations into 2025...
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people...
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people...